Sanofi-Aventis announces R&D restructuring

Share this article:
Sanofi-Aventis announced plans to restructure its R&D model, set to be completed by 2013. 

No layoffs will result from the restructuring, according to the statement (pdf), although some 1,300 employees will be eligible for “voluntary departures,” according to the Wall Street Journal. Company locations in the UK, Japan and Spain will be closed, along with four sites in France, with a fifth being divested. 

Around 650 people will be shuffled into different locations or jobs in France, according to the statement.

“The objective of this new R&D model is to propose innovate solutions that respond to specific, unmet needs of patients and continue our success in a very competitive international environment, said Chris Viehbacher, CEO, in the statement.
Share this article:

Email Newsletters

More in News

Astellas, DOJ settle for $7.3M

Astellas, DOJ settle for $7.3M

Astellas has settled a False Claims case with the Department of Justice over the 2010-2013 marketing of an antifungal medication. Astellas denies the allegations.

Boehringer drug lands US, EU orphan tag

Boehringer drug lands US, EU orphan tag

The experimental Breakthrough Therapy treatment is for acute myeloid leukemia.

Omnio app moves to smartphones

Omnio app moves to smartphones

Physicians Interactive is introducing the third wave of its Omnio app, making the tablet-only tool available for iPhones and Android phones.